We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Crystal Structure of Key Ebolavirus Protein Reported

By LabMedica International staff writers
Posted on 26 Jan 2009
A team of molecular biologists has solved the structure of an Ebolavirus protein that may be responsible for the ability of the virus to invade and infect mammalian cells.

Investigators at Iowa State University (Ames, USA) used a combination of X-ray crystallography and nucleic magnetic resonance spectroscopy (NMR) to solve the structure of a noninfectious sample of the Ebola VP35 protein. More...
This protein plays several roles in the viral metabolism, acting as a component of the viral RNA polymerase complex, a viral assembly factor, and an inhibitor of host interferon (IFN) production. Mutation of select basic residues within the C-terminal half of VP35 eliminates its ability to bind double stranded RNA (dsRNA), impairs VP35-mediated IFN antagonism, and slows growth of the virus in vitro and in vivo.

Results published in the January 2, 2009 online edition of the journal Proceedings of the [U.S.] National Academy of Sciences (PNAS) revealed that at a resolution of 1.4 Angstroms VP35 formed a unique fold. In this fold resided two basic residue clusters, one of which was important for dsRNA binding. The dsRNA-binding cluster was centered on Arg-312 (arginine-312), a highly conserved residue required for IFN inhibition. Mutation of residues within this cluster significantly changed the surface electrostatic potential and diminished dsRNA-binding activity.

"Usually when viruses infect cells, the host immune system can fight to eventually clear the virus. But with Ebola infections, the ability of the host to mount a defense against the invading virus is lost," said senior author Dr. Gaya Amarasinghe, assistant professor in biochemistry, biophysics, and molecular biology at Iowa State University. "The next step is to use this structure to identify and design drugs that potentially bind with VP35. Without functional VP35, the Ebolavirus cannot replicate so it is noninfectious."

Related Links:
Iowa State University



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The circulating tumor DNA blood test could provide earlier warning of post-transplant recurrence (Photo courtesy of Shutterstock)

Blood Test Could Enable Earlier Detection of Liver Cancer Recurrence After Transplant

Liver cancer is a leading cause of cancer deaths worldwide, with more than 800,000 diagnoses and over 700,000 deaths each year. Disease recurrence after liver transplantation is common and is associated... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.